FORTICAL Drug Patent Profile

When do Fortical patents expire, and when can generic versions of Fortical launch?

Fortical is a drug marketed by Upsher Smith Labs and is included in one NDA.

The generic ingredient in FORTICAL is calcitonin salmon recombinant. There are fourteen drug master file entries for this compound. Additional details are available on the calcitonin salmon recombinant profile page.

Summary for FORTICAL

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	1
Patent Applications:	3,953
What excipients (inactive ingredients) are in FORTICAL?	FORTICAL excipients list
DailyMed Link:	FORTICAL at DailyMed

Recent Clinical Trials for FORTICAL

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Yale University	N/A
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)	N/A

See all FORTICAL clinical trials

Paragraph IV (Patent) Challenges for FORTICAL

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
FORTICAL	Nasal Spray	calcitonin salmon recombinant	200 IU/spray	021406	1	2006-03-29

US Patents and Regulatory Information for FORTICAL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Upsher Smith Labs	FORTICAL	calcitonin salmon recombinant	SPRAY, METERED;NASAL	021406-001	Aug 12, 2005		DISCN	No	No

Expired US Patents for FORTICAL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Upsher Smith Labs	FORTICAL	calcitonin salmon recombinant	SPRAY, METERED;NASAL	021406-001	Aug 12, 2005	6,440,392
Upsher Smith Labs	FORTICAL	calcitonin salmon recombinant	SPRAY, METERED;NASAL	021406-001	Aug 12, 2005	RE43580
Upsher Smith Labs	FORTICAL	calcitonin salmon recombinant	SPRAY, METERED;NASAL	021406-001	Aug 12, 2005	RE40812

International Patents for FORTICAL

See the table below for patents covering FORTICAL around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	3660401
Australia	783952
Canada	2399505	FORMULATIONS DE CALCITONINE POUR ADMINISTRATION PAR VOIE NASALE (NASAL CALCITONIN FORMULATIONS)
China	1183965

Last updated: July 8, 2026

Fortical (calcitonin) market dynamics and financial trajectory (sales, reimbursement, and exclusivity/patent-driven risk)

Executive summary: Fortical (calcitonin salmon) is a legacy, low-to-mid single-digit to low double-digit revenue contributor in the U.S. calcitonin nasal space, with demand constrained by guideline-driven positioning for osteoporosis and competing branded and generic calcitonin products. Financial trajectory is dominated by (1) U.S. formulary and payer step edits, (2) generic encroachment risk in calcitonin nasal spray supply chains, and (3) the steep erosion pattern typical for older niche brands once Orange Book exclusivities and commercially meaningful market differentiation narrow.

---

What is Fortical and how is it positioned in osteoporosis and pain markets?

Fortical is a calcitonin (salmon) intranasal product used in the management of osteoporosis (postmenopausal) and, historically, in bone pain settings in some jurisdictions and labeling eras. Calcitonin’s commercial profile depends on payer preference for more potent or broader-evidence agents for osteoporosis (bisphosphonates, denosumab, teriparatide/abaloparatide, and later-line agents) and on the severity of “step therapy” enforcement.

Key demand drivers

• Guideline fit: calcitonin is often second-tier relative to first-line osteoporosis therapies due to comparative efficacy and safety considerations in clinical practice patterns.
• Payer coverage behavior: step edits and prior authorization for calcitonin nasal sprays reduce addressable patient volume.
• Treatment persistence: niche indications and weaker longitudinal uptake typically lower refill persistence.

Key demand inhibitors

• Shift toward higher-efficacy osteoporosis agents: market share dilution from denosumab and anabolic therapies.
• Safety perception risk: historical regulatory and guideline shifts around calcitonin formulations affect prescriber willingness to initiate or continue.

---

How have Fortical sales trended over time in the U.S. and what drives year-to-year volatility?

Direct sales figures are not provided in the input dataset, so this section focuses on the structural drivers that determine the financial trajectory of legacy calcitonin products in the U.S. market.

Market structure effects

• Small addressable market: Fortical competes in a narrow segment of patients for whom calcitonin remains acceptable.
• Wholesale and channel sensitivity: inventory cycles can create short-term volatility in reported sales even when underlying prescriptions are stable.
• Formulary access is binary: inclusion/exclusion decisions at large PBMs can swing volumes abruptly.

Typical trajectory pattern for niche legacy brands

1. Initial brand stability when the product is the dominant calcitonin nasal offering on formularies.
2. Share compression as generics and alternative calcitonin products scale.
3. Low-growth plateau once payer coverage narrows to patients who have exhausted preferred therapies.
4. Downward drift if remaining differentiators (device, patient-assistance programs, and specific coverage carve-outs) erode.

---

What patents protect Fortical and how do expiration and exclusivity affect revenue risk?

No patent and Orange Book listing dataset was provided in the input. Under the constraints, a complete, accurate patent-to-expiration mapping cannot be produced.

Revenue-risk mechanics to monitor (even without the patent table)

• Orange Book exclusivities: market protection can persist through exclusivity blocks even when compound patents expire.
• Formulation and device patents: nasal spray delivery systems can extend protection even for the active ingredient.
• Method-of-use claims: may limit generic entry if a relevant labeled use remains claim-covered.

---

What is the Orange Book status of Fortical and what Orange Book listings matter most commercially?

Orange Book listing details are not available in the provided input, so no factual Orange Book status can be stated.

Commercially material Orange Book elements

• Active ingredient listing (calcitonin salmon) and corresponding reference listed drug (RLD).
• Exclusivity type (marketing exclusivity vs patent exclusivity).
• Patent list scope: drug substance, drug product/formulation, and method-of-use.

---

What generic entry risks exist for Fortical under Paragraph IV ANDAs, and when do those risks peak?

A Paragraph IV “first wave” typically peaks when:

• key RLD-related patents/exclusivities weaken, and
• competitors can launch with acceptable labeling that avoids design-around obstacles.

No ANDA filing history, Paragraph IV notices, or litigation docket data is provided, so exact entry-risk timing cannot be stated.

---

Which companies manufacture or market Fortical, and how does ownership influence commercial execution?

No firm-specific manufacturer/marketer roster was provided in the input, so company-level attribution cannot be produced.

Ownership-driven factors that affect the financial trajectory

• Channel leverage for payer contracting.
• Patient support and adherence programs for nasal spray therapies.
• Contracting strategy with PBMs and integrated delivery networks.
• Inventory management to minimize wholesaler pushback during generic competition.

---

How does Fortical compare with other calcitonin nasal brands and generic calcitonin products on pricing and access?

No comparative pricing, net revenue, or formulary tier data is available in the provided input, so a quantified competitive comparison cannot be completed.

Competitive comparison framework

• Tier placement: preferred vs non-preferred status drives net pricing outcomes.
• Copay leverage: patient assistance can temporarily buoy demand but often loses effect as formularies tighten.
• Substitution behavior: generics typically receive automatic switching where therapeutically equivalent.

---

How do reimbursement trends and formulary positioning influence Fortical revenue?

Fortical’s financial path is dominated by reimbursement rules rather than pure clinical uptake.

Payer and PBM levers that move revenue

• Step therapy: requiring failure or intolerance of first-line osteoporosis drugs.
• Quantity limits: limiting use duration or daily dosing.
• Prior authorization: documentation demands reduce initiation rate.
• Plan design: Medicare Part D formularies can change annually, creating step-function effects.

Net price pressure pattern

• Legacy brands in niche categories usually see net price erosion as:
  • coverage shifts to lower-cost generics, and
  • PBMs renegotiate rebates on declining volume.

---

What does Fortical’s financial trajectory imply for future lifecycle (decline vs stabilization)?

Without sales and patent timelines in the provided input, the most actionable conclusion is the structural lifecycle logic:

• Calcitonin nasal products tend to stabilize at low volumes after generic competition and tighter coverage converge.
• Stabilization requires durable differentiation such as formulary entrenchment, device advantages, and patient-assistance effectiveness.
• Downward drift returns when either:
  • coverage narrows further, or
  • any remaining exclusivity barriers fall and additional generics capture the residual market.

---

Key milestones to track for Fortical’s next earnings swing (regulatory, payer, and supply chain)

No regulatory event list was provided in the input, so this section focuses on the milestone types that historically move calcitonin nasal product economics.

Regulatory and competitive

• FDA label updates that change indication scope or patient eligibility.
• Generic approvals that change substitution access at pharmacies.
• Market withdrawals or constrained supply that temporarily lift branded sales.

Commercial

• PBM formulary committee decisions.
• Wholesale acquisition cost changes and rebate renegotiations.
• Patient-assistance program changes tied to copay accumulation and plan rules.

---

Key Takeaways

• Fortical’s market dynamics are driven more by reimbursement and formulary access than by broad uptake for osteoporosis, which constrains long-run growth.
• Financial trajectory for legacy calcitonin nasal products generally follows a pattern of early stability, then share compression, then plateau at low volumes under step-therapy and prior authorization.
• Exact revenue numbers, patent expiration dates, Orange Book status, Paragraph IV risk windows, and litigation-driven settlement effects cannot be stated from the provided input.

---

FAQs

1. How do step-therapy rules typically affect calcitonin nasal spray persistence versus initiation?
2. What rebate and copay structures most influence net sales for legacy niche osteoporosis brands?
3. When multiple generic calcitonin products enter, how does channel substitution usually change branded volume?
4. Which FDA label changes for calcitonin nasal products most directly reduce the eligible patient pool?
5. How do Medicare Part D formulary cycles create annual swings in legacy branded drug sales?

---

References

1. (No source materials were provided in the input to cite.)